dIFine 30 system is ZEUS Scientific’s complete solution for IFA slide processing and digital immunofluorescence imaging

dIFine 30 System
A complete system for IFA slide processing and digital immunofluorescence imaging – including cover slipping!

BRANCHBURG, N.J., March 17, 2023 (Newswire.com)
–
Today, ZEUS Scientific launched the dIFine 30 System, a powerful partnership pairing the ZEUS dIFine® digital immunofluorescence system with the new ZEUS SP30 slide processor. The SP30 is an easy-to-use and efficient walk-away benchtop instrument for IFA slide processing, designed to improve laboratory workflow and ensure high-quality results, including cover slipping. The SP30 can process up to 240 samples on 30 ZEUS IFA slides. With its three-probe system for fast, accurate pipetting and slide well washing, it precisely dispenses mounting media and adds coverslips, decreasing slide handling and the risk of artifacts/bubbles. The multi-drop individual well-to-well washing eliminates the risk of carryover or cross-contamination. ZEUS ANA IFA test kits feature ready-to-use reagents that can be directly loaded onto the SP30 – no pour off. Its user-friendly, intuitive software works with ZEUS dIFine, allowing for parallel processing and scanning sessions. The system connects to laboratories’ LIS to receive test requests and share the worklist with dIFine, boosting efficiency.

The FDA-cleared ZEUS dIFine System is the next generation in IFA imaging, interpretation, and pattern recognition, designed to acquire, analyze, display and store digital images of ZEUS IFA HEp-2 cells. An automated digital scanner with intelligent software, dIFine quickly delivers positive/negative results and is FDA-cleared to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal and mitochondrial)).* dIFine also instantly locates and identifies mitotic cells, assisting in pattern identification. The ability to quickly view/validate all negative samples saves users valuable time. The built-in pattern atlas can be used as a reference or training tool, allowing side-by-side comparison with ZEUS proprietary images aligned with ICAP nomenclature.

ANA HEp-2 IFA is the American College of Rheumatology (ACR) gold standard for ANA testing. A pioneer in IFA technology, ZEUS has continually delivered quality products and expertise in autoimmune serology that laboratories have relied upon since 1976.

For 45+ years, laboratories have trusted ZEUS Scientific to provide high-quality IFA ANA HEp-2 products. The ZEUS proprietary cell fixation process allows technologists to work with cells containing natural, unaltered antigens and provides clear, crisp images; excellent cell morphology; and a high number of mitotic cells, all which make pattern determination easier.

With this new launch, laboratories can take their ANA IFA testing to the next level by pairing ZEUS’s top-tier IFA ANA HEp-2 slides with the ZEUS dIFine 30 System. In addition, ZEUS is in the final phases of FDA submission for dIFine automated negative/positive determination and detection of anti-dsDNA (nDNA/Crithidia) antibodies in 2023.

For more information, please visit the ZEUS website or contact the ZEUS sales team.

_{* FDA 510(k) cleared. All suggested results obtained with ZEUS dIFine must be confirmed by a trained operator.}

Contact Information:

Travis Smyre

Vice President Commercial

[email protected]

908-243-4911

Original Source:

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System

dIFine 30 system is ZEUS Scientific’s complete solution for IFA slide processing and digital immunofluorescence imaging

dIFine 30 System
A complete system for IFA slide processing and digital immunofluorescence imaging – including cover slipping!

BRANCHBURG, N.J., March 17, 2023 (Newswire.com)
–
Today, ZEUS Scientific launched the dIFine 30 System, a powerful partnership pairing the ZEUS dIFine® digital immunofluorescence system with the new ZEUS SP30 slide processor. The SP30 is an easy-to-use and efficient walk-away benchtop instrument for IFA slide processing, designed to improve laboratory workflow and ensure high-quality results, including cover slipping. The SP30 can process up to 240 samples on 30 ZEUS IFA slides. With its three-probe system for fast, accurate pipetting and slide well washing, it precisely dispenses mounting media and adds coverslips, decreasing slide handling and the risk of artifacts/bubbles. The multi-drop individual well-to-well washing eliminates the risk of carryover or cross-contamination. ZEUS ANA IFA test kits feature ready-to-use reagents that can be directly loaded onto the SP30 – no pour off. Its user-friendly, intuitive software works with ZEUS dIFine, allowing for parallel processing and scanning sessions. The system connects to laboratories’ LIS to receive test requests and share the worklist with dIFine, boosting efficiency.

The FDA-cleared ZEUS dIFine System is the next generation in IFA imaging, interpretation, and pattern recognition, designed to acquire, analyze, display and store digital images of ZEUS IFA HEp-2 cells. An automated digital scanner with intelligent software, dIFine quickly delivers positive/negative results and is FDA-cleared to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal and mitochondrial)).* dIFine also instantly locates and identifies mitotic cells, assisting in pattern identification. The ability to quickly view/validate all negative samples saves users valuable time. The built-in pattern atlas can be used as a reference or training tool, allowing side-by-side comparison with ZEUS proprietary images aligned with ICAP nomenclature.

ANA HEp-2 IFA is the American College of Rheumatology (ACR) gold standard for ANA testing. A pioneer in IFA technology, ZEUS has continually delivered quality products and expertise in autoimmune serology that laboratories have relied upon since 1976.

For 45+ years, laboratories have trusted ZEUS Scientific to provide high-quality IFA ANA HEp-2 products. The ZEUS proprietary cell fixation process allows technologists to work with cells containing natural, unaltered antigens and provides clear, crisp images; excellent cell morphology; and a high number of mitotic cells, all which make pattern determination easier.

With this new launch, laboratories can take their ANA IFA testing to the next level by pairing ZEUS’s top-tier IFA ANA HEp-2 slides with the ZEUS dIFine 30 System. In addition, ZEUS is in the final phases of FDA submission for dIFine automated negative/positive determination and detection of anti-dsDNA (nDNA/Crithidia) antibodies in 2023.

For more information, please visit the ZEUS website or contact the ZEUS sales team.

_{* FDA 510(k) cleared. All suggested results obtained with ZEUS dIFine must be confirmed by a trained operator.}

Contact Information:

Travis Smyre

Vice President Commercial

[email protected]

908-243-4911

Original Source:

ZEUS Scientific Introduces the SP30 IFA Slide Processor for dIFine as Part of the dIFine 30 System

Northwind Pharmaceuticals, a rapidly growing national provider of prescription medications, chronic care programs, and pharmacy benefits, adds market innovation strategist John Singer to its strategic advisory board.
…

All-On-4 dental implants offered by Inspire Dental Wellness are a popular and durable choice for full-mouth dental reconstructions.

All-On-4 implan…

All-On-4 dental implants offered by Inspire Dental Wellness are a popular and durable choice for full-mouth dental reconstructions.

All-On-4 implan…

Patients receive personal, customized care from board-certified physicians, registered nurses, behavioral technicians, and other healthcare professionals.

…

ART MEDICAL Ltd. is pleased to announce its collaboration with Teva Israel. Under the terms of the agreement, Teva Israel will market and distribute ART MEDICAL’s ground-breaking smART+ Platform in Israel’s intensive care units.

NETANYA, Israel, March 16, 2023 (Newswire.com)
–
The smART+ Platform is a robotic-assisted technology that aims to reduce complications related to feeding tube malposition, malnutrition, Ventilator-Associated Pneumonia (VAP), and Acute Kidney Injury (AKI). By delivering transformative new-to-the-world data, the smART+ Platform enables medical staff to take a comprehensive approach to critical care, make informed decisions and improve patient outcomes. 

Current related practices in intensive care units rely mostly on manual work and cumbersome procedures. ICU patients are routinely subjected to the risks of malnutrition, tube malposition, and pneumonia. Without technological solutions, nutrition treatment leads to inaccuracies, increased workloads on care teams, and generic nutrition plans that are neither personalized nor updated in real time. The smART+ Platform uses a proprietary sensor-based feeding tube, continuous metabolic assessment, and algorithms, to provide real-time monitoring and closed-loop feedback, resulting in better and personalized care for critically ill patients. 

ART MEDICAL’s Founder and CEO, Liron Elia, says, “Our goal, at ART MEDICAL, is to improve patient outcomes through cutting-edge technology. By integrating real-time data, monitoring, and control mechanisms, the smART+ Platform addresses several of the greatest clinical challenges of intensive care units. This powerful combination provides a comprehensive and innovative nutritional therapy practice as well as optimized care delivery. We are thrilled to partner with Teva Israel to bring our technology to critically ill patients and clinical teams in ICUs.”

Yossi Ofek, GM-Teva Israel, SVP; Cluster Head – Middle East, Africa & Ukraine says:

“Teva Israel continually strives to offer innovative and safe treatment options – both in the community and in hospitals – in order to improve the lives and health of patients.

“The innovative development of an Israeli company, ART MEDICAL, is intended to ensure that patients in intensive care units receive the most advanced treatment offered today that can minimize complications related to hospitalization and reduce length of stay.”

About Teva Israel:

‘Teva Israel’ is the home-based marketing arm of Teva Pharmaceutical Industries Ltd, where it has been working to improve the lives and health of patients, for over 120 years, through high-quality and affordable medicines.

As a leading player in the local health market and particularly in the generics and OTC markets, Teva Israel provides unique services in Israel to Israeli residents, through its logistics company SLE – and markets a wide variety of medicines and products: from original innovative medicines and generic medicines, through medical equipment and devices for hospitals, to over the counter (OTC) medicines and baby milk formula.

Teva Israel is also an innovation incubator for Teva Global and established, in collaboration with Philips, Sanara Ventures, a platform for investments in start-up companies in the fields of digital medicine and medical devices. In Israel, one of every four prescriptions is for a Teva drug, while the annual savings that the company’s generic drugs bring to the Israeli healthcare system is estimated at about one and a half billion shekels, per year.

About ART MEDICAL

ART MEDICAL is on a mission to save lives through technological innovations and redefine the future of critical care. Our goal is to see ICU patients get better faster with the help of real-time nutrition management. Visit www.artmedical.com or follow us on LinkedIn for more information. 

Forward-Looking Statements of ART MEDICAL

ART MEDICAL developed the smART+™ Platform as a holistic approach for the next-generation ICU, featuring an ecosystem of sensor-based tools, software, and algorithms. smART+ is designed to prevent ICU-acquired complications. The smART+ Platform aims to reduce length of ventilation days and length of stay that are attributed to malnutrition, VAP, and other secondary infections and complications, ultimately providing better care, and dramatically reducing healthcare costs.

Disclaimer

THIS PRESS RELEASE AND ITS CONTENT IS NOT INTENDED AS AN OFFERING OR AS A SOLICITATION TO AN OFFERING TO PURCHASE SECURITIES OF ANY OF THE ABOVE-MENTIONED COMPANIES OR ANY OF THEIR AFFILIATES, DIRECTLY OR INDIRECTLY, AND YOU MAY NOT RELY ON THIS PRESS RELEASE IN CONNECTION WITH AN INVESTMENT DECISION.

Contact Information:

Ori Braun

SVP Business Development

[email protected]

Original Source:

ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving Technology to Critical Care Units

AmplifyBio builds on the T-cell immunology expertise of its South San Francisco-based team, adding technology platforms and capabilities in single-cell analysis and product assessment in the context of a tumor microenv…

The addition of remote patient monitoring – coupled with additional health metrics – gives healthcare providers extended reach and improved variables to enable better outcomes for concussed patients.

…

Space-age Technology Changes Cataract Surgery in Utah

Bryan Monson, MD, performing cataract surgery Bryan Monson, MD, performing modern laser-ass…